

13th February, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM
---	--

Sub: Outcome of Board Meeting held on 13th February, 2026

Dear Sir(s)/ Madam,

This is with reference to our earlier intimation dated 23rd January, 2026, pursuant to Regulation 30 read with Regulation 33, Regulation 42 and Regulation 43 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), the Board of Directors of the Company, at its meeting held today i.e. 13th February, 2026 have *inter alia*:

- a. Approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2025.

A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations, is enclosed herewith.

- b. Declared an Interim Dividend of Rs. 43/- (Rupees forty-three only) per equity share on the face value of Rs. 2/- per share for financial year 2025-2026 pursuant to Regulation 43 read with Regulation 30 of SEBI LODR Regulations.


The date of payment of Interim Dividend shall be on and from 6th March, 2026.

Further, as informed vide our letter dated 23rd January, 2026, submitted to the Stock Exchanges pursuant to Regulation 42 of SEBI LODR Regulations, the record date for the purpose of payment of Interim Dividend for financial year 2025-2026 would be Friday, 20th February, 2026.

The meeting of the Board of Directors of the Company commenced at 11:00 a.m. and concluded at 01:45 p.m.

Kindly take the same on record.

Sincerely,
For Alkem Laboratories Limited



Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Alkem Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive income of its associate for the quarter and nine months ended December 31, 2025 ("the Statement") which includes one branch of the Group located at Nepal being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of four subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 3,120.9 million and Rs. 9,071.6 million for the quarter and nine months ended December 31, 2025 respectively, total net profit after tax of Rs. 343.6 million and Rs. 717.7 million for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income of Rs. 431.4 million and Rs. 828.7 million for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial information of eighteen subsidiaries which have not been reviewed by their auditors, whose financial information reflect total revenue of Rs. 2,951.8 million and Rs. 8,269.2 million for the quarter and nine months ended December 31, 2025 respectively, total net loss after tax of Rs. 254.4 million and Rs. 119.6 million for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income of Rs. (236.3) million and Rs. (70.5) million for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. 5.0 million and Rs. 14.0 million for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income of Rs. (5.0) million and Rs. (14.0) million for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement, in respect of one associate, based on its interim financial information which has not been reviewed by its auditor. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information / results certified by the Management.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Rupen K. Bhatt
(Partner)
(Membership No. 046930)
(UDIN: 26046930CFOAM12835)

 Place: Mumbai
Date: February 13, 2026

ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date)

Sr No	Name of the component	Relationship
1	Alkem Laboratories Limited	Parent
2	S&B Holdings S.a.r.l,	Wholly Owned Subsidiary
3	The Pharma Network LLC, USA (TPN)	Wholly Owned Subsidiary
4	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5	S & B Pharma LLC	Wholly Owned Subsidiary of TPN
6	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7	Pharmacor SPA, Chile	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
8	Enzene Biosciences Ltd, India	Subsidiary
9	Ascend Laboratories (PTY) Ltd, South Africa	Wholly Owned Subsidiary
10	Cachet Pharmaceuticals Pvt Ltd	Subsidiary
11	Indchemie Health Specialities Pvt Ltd, India	Subsidiary
12	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
13	Ascend GmbH, Germany	Wholly Owned Subsidiary
14	Ascend Laboratories SON BHD., Malaysia	Wholly Owned Subsidiary
15	Ascend Laboratories SpA Chile (Ascend Chile)	Wholly Owned Subsidiary
16	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
17	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
18	Alkem Laboratories Korea Inc Korea	Wholly Owned Subsidiary
19	Pharmacor Ltd, Kenya	Wholly Owned Subsidiary
20	The Pharma Network LLP, Kazakhstan	Wholly Owned Subsidiary
21	Ascend Laboratories (UK) Ltd, UK	Wholly Owned Subsidiary
22	Ascend Laboratories Ltd, Canada	Wholly Owned Subsidiary
23	Alkem Foundation. India	Wholly Owned Subsidiary
24	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
25	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
26	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary
27	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India
28	Alkem Medtech Private Limited, India	Wholly Owned Subsidiary
29	Alixer Nexgen Therapeutics Limited	Wholly Owned Subsidiary
30	Alkem Wellness Limited	Wholly Owned Subsidiary
31	Adroit Biomed Limited	Wholly Owned Subsidiary
32	Alkem Medtech Ortho Private Limited (formerly known as Bombay Ortho Industries Private Limited)	Wholly Owned Subsidiary of Alkem Medtech Private Limited, India
33	Haystack Analytics Private Limited	Associate

R
D

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Consolidated Financial Results for the Quarter and Nine months ended 31 December 2025

(₹ in Million except per share data)

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025 Unaudited	30.09.2025 Unaudited	31.12.2024 Unaudited	31.12.2025 Unaudited	31.12.2024 Unaudited	31.03.2025 (Audited)
1	Income						
	(a) Revenue from Operations	37,368.2	40,009.9	33,742.8	111,089.5	98,207.7	129,645.2
	(b) Other Income	1,431.0	1,036.9	929.9	3,832.8	3,477.8	4,937.4
	Total Income	38,799.2	41,046.8	34,672.7	114,922.3	101,685.5	134,582.6
2	Expenses						
	(a) Cost of materials consumed	9,377.7	9,055.7	9,240.1	26,704.5	26,633.4	34,403.7
	(b) Purchases of stock-in-trade	3,279.6	4,715.7	3,974.8	11,967.3	11,340.6	15,140.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	69.8	238.9	(1,171.6)	(222.8)	(3,124.2)	(1,901.3)
	(d) Employee benefits expense	7,215.1	7,102.5	6,248.1	21,250.1	18,375.7	24,539.2
	(e) Finance costs	421.0	350.2	360.3	1,069.0	932.8	1,217.0
	(f) Depreciation and amortisation expense	950.1	936.1	852.8	2,763.0	2,446.7	3,571.6
	(g) Other expenses	9,146.0	9,689.4	7,857.5	26,512.2	23,773.6	32,341.9
	Total Expenses	30,459.3	32,088.5	27,362.0	90,043.3	80,378.6	109,312.3
3	Profit before exceptional items and tax (1) - (2)	8,339.9	8,958.3	7,310.7	24,879.0	21,306.9	25,270.3
4	Exceptional items (refer note 3)	(527.9)	-	-	(398.6)	-	-
5	Profit before tax (3) + (4)	7,812.0	8,958.3	7,310.7	24,480.4	21,306.9	25,270.3
6	Tax expense / (credit)						
	(a) Current tax	1,769.7	1,799.5	1,590.4	4,980.3	4,393.5	5,236.0
	(b) Deferred tax	(493.0)	(637.2)	(687.6)	(1,514.4)	(2,016.5)	(2,125.7)
	Total Tax Expense (a + b)	1,276.7	1,162.3	902.8	3,465.9	2,377.0	3,110.3
7	Share in loss after tax of associate	(5.0)	(4.9)	-	(14.0)	-	(6.2)
8	Profit for the period (5) - (6) + (7)	6,530.3	7,791.1	6,407.9	21,000.5	18,929.9	22,153.8
9	Other Comprehensive Income (net of tax)						
	(a) (i) Items that will not be reclassified to profit or loss	(141.2)	(44.9)	(37.6)	(233.7)	(153.8)	(218.1)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	50.8	26.6	13.0	80.3	50.4	72.1
	(b) (i) Items that will be reclassified to profit or loss	326.1	447.0	145.6	838.6	326.5	343.2
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (net of tax)	235.7	428.7	121.0	685.2	223.1	197.2
10	Total Comprehensive Income for the period (8) + (9)	6,766.0	8,219.8	6,528.9	21,685.7	19,153.0	22,351.0
11	Profit attributable to						
	a) Owners of the Company	6,360.2	7,650.6	6,258.2	20,653.4	18,596.2	21,654.8
	b) Non-Controlling Interest	170.1	140.5	149.7	347.1	333.7	499.0
12	Other Comprehensive Income attributable to						
	a) Owners of the Company	235.2	432.4	120.7	690.7	233.3	207.5
	b) Non-Controlling Interest	0.5	(3.7)	0.3	(5.5)	(10.2)	(10.3)
13	Total Comprehensive Income attributable to						
	a) Owners of the Company	6,595.4	8,083.0	6,378.9	21,344.1	18,829.5	21,862.3
	b) Non-Controlling Interest	170.6	136.8	150.0	341.6	323.5	488.7
14	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1	239.1	239.1
15	Other Equity						119,609.6
16	Earnings Per Share (not annualised for the periods) (face value of ₹ 2/- each)						
	(a) Basic (₹)	53.19	63.99	52.34	172.74	155.54	181.11
	(b) Diluted (₹)	53.19	63.99	52.34	172.74	155.54	181.11

Notes to the Consolidated Financial results:


- 1 The above consolidated financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 12 February 2026 and subsequently approved by the Board of Directors at its meeting held on 13 February 2026. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2025.
- 3 Exceptional items include:
 - a) The Government of India notified the four Labour Codes which are effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed the incremental impact of these changes on the basis of the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India.

The incremental impact basis preliminary analysis of ₹527.9 million is classified and disclosed as an exceptional item in the results for the quarter and nine months ended 31 December 2025. The Group continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate financial impact on the basis of such developments as needed.
 - b) The Parent Company sold its Indore manufacturing facility in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to ₹142.9 million had been classified and disclosed as an exceptional item in the results for the nine months ended 31 December 2025.
- 4 The Board of Directors at its meeting held on 13 February 2026 have declared an interim dividend of ₹ 43 (Rupees Forty Three only) per equity share (2150% on the face value of ₹ 2 each) for the financial year ending 31 March 2026.
- 5 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.



Place: Mumbai
Date: 13 February 2026

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Alkem Laboratories Limited** ("the Company"), which includes a branch located at Nepal, for the quarter and nine months ended December 31, 2025, ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**

Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Rupen K. Bhatt
(Partner)

(Membership No. 046930)
(UDIN:26046930PMYHKL6517)



Place: Mumbai
Date: February 13, 2026

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Standalone Financial Results for the Quarter and Nine months ended 31 December 2025

(₹ in Million except per share data)							
	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	
1	Continuing Operations						
	Income						
	(a) Revenue from Operations	24,912.7	25,420.3	22,868.3	74,054.7	67,685.0	88,134.4
	(b) Other Income	1,315.3	1,013.7	1,691.8	3,494.8	3,954.7	5,070.6
	Total Income	26,228.0	26,434.0	24,560.1	77,549.5	71,639.7	93,205.0
2	Expenses						
	(a) Cost of materials consumed	5,875.1	5,676.3	6,931.3	17,704.7	19,445.1	23,959.2
	(b) Purchases of stock-in-trade	1,131.0	1,228.4	1,209.0	3,194.5	3,043.7	3,896.1
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	156.7	(26.0)	(881.5)	210.0	(1,305.3)	566.1
	(d) Employee benefits expense	4,855.8	4,608.5	4,184.8	14,161.7	12,293.3	16,309.6
	(e) Finance costs	155.1	127.5	210.0	410.5	592.0	761.1
	(f) Depreciation and amortisation expenses	609.1	585.9	676.1	1,783.9	1,919.7	2,836.1
	(g) Other expenses	6,002.0	6,226.3	4,846.4	17,980.1	15,614.1	21,841.4
	Total Expenses	18,784.8	18,426.9	17,176.1	55,445.4	51,602.6	70,169.6
3	Profit before exceptional items and tax from continuing operations (1) - (2)	7,443.2	8,007.1	7,384.0	22,104.1	20,037.1	23,035.4
4	Exceptional items (Refer note 4)	(381.7)	-	-	(238.8)	-	-
5	Profit before tax from continuing operations (3) + (4)	7,061.5	8,007.1	7,384.0	21,865.3	20,037.1	23,035.4
6	Tax expense / (credit)						
	(a) Current tax	1,243.9	1,235.6	1,198.8	3,572.9	3,133.8	3,501.3
	(b) Deferred tax	(403.8)	(465.1)	(577.1)	(1,388.2)	(1,735.1)	(1,363.1)
	Total Tax expense (a + b)	840.1	770.5	621.7	2,184.7	1,398.7	2,138.2
7	Profit for the period after tax from continuing operations (5 - 6)	6,221.4	7,236.6	6,762.3	19,680.6	18,638.4	20,897.2
	Discontinued operations (Refer note 3)						
	Profit before tax from discontinued operations	-	969.5	720.7	1,490.5	2,153.7	2,938.5
	Tax expense of discontinued operations	-	338.8	251.8	520.8	752.6	1,026.8
8	Profit from discontinued operations (after tax)	-	630.7	468.9	969.7	1,401.1	1,911.7
9	Profit for the period (7) + (8)	6,221.4	7,867.3	7,231.2	20,650.3	20,039.5	22,808.9
10	Other Comprehensive Income (net of tax)						
	I. In respect of continuing operations:						
	(a) (i) Items that will not be reclassified to profit or loss	(147.0)	(31.3)	(39.9)	(209.7)	(119.5)	(170.3)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	51.3	11.0	14.0	73.3	41.8	59.5
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	II. In respect of discontinued operations:						
	(a) (i) Items that will not be reclassified to profit or loss	-	(1.9)	1.6	(3.6)	4.7	(6.5)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	0.6	(0.6)	1.2	(1.7)	2.3
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (net of tax)	(95.7)	(21.6)	(24.9)	(138.8)	(74.7)	(115.0)
11	Total Comprehensive Income for the period (9) + (10)	6,125.7	7,845.7	7,206.3	20,511.5	19,964.8	22,693.9
12	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1	239.1	239.1
13	Other Equity						122,979.2
14	Earnings Per Share (not annualised for the periods) (for continuing operations) (face value of ₹ 2/- each)						
	(a) Basic (₹)	52.03	60.53	56.56	164.60	155.89	174.78
	(b) Diluted (₹)	52.03	60.53	56.56	164.60	155.89	174.78
	Earnings Per Share (not annualised for the periods) (for discontinued operations) (face value of ₹ 2/- each)						
	(a) Basic (₹)	-	5.27	3.92	8.11	11.71	15.99
	(b) Diluted (₹)	-	5.27	3.92	8.11	11.71	15.99
	Earnings Per Share (not annualised for the periods) (from total operations) (face value of ₹ 2/- each)						
	(a) Basic (₹)	52.03	65.80	60.48	172.71	167.60	190.77
	(b) Diluted (₹)	52.03	65.80	60.48	172.71	167.60	190.77

Notes to the Standalone Financial results:

- 1 The above standalone financial results are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 12 February 2026 and subsequently approved by the Board of Directors at its meeting held on 13 February 2026. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2025.
- 3 The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited.

During the earlier periods, the proposed transfer of the Generic Business has been disclosed as discontinued operations in accordance with Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations". The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 "Non - current Assets Held for Sale and Discontinued Operations".

Key financial information of Discontinued Operations:

Particulars	Quarter ended			Nine months ended		(₹ in Million)
	31.12.2025	30.09.2025	31.12.2024	31.12.2025*	31.12.2024	Year ended 31.03.2025
Total income	-	5,622.8	4,880.4	9,181.0	13,784.4	18,974.9
Total expenses	-	4,653.3	4,159.7	7,690.5	11,630.7	16,036.4
Profit before tax	-	969.5	720.7	1,490.5	2,153.7	2,938.5
Total tax expense	-	338.8	251.8	520.8	752.6	1,026.8
Net profit for the period after tax	-	630.7	468.9	969.7	1,401.1	1,911.7

*Note: The figures for the nine months ended 31 December 2025 are not comparable with those of the corresponding period, as they reflect carved-out results up to 30 September 2025, the date on which the generic business was transferred to Alkem Wellness Limited.

- 4 Exceptional items include:

a) The Government of India notified the four Labour Codes which are effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the incremental impact of these changes on the basis of the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India.


The incremental impact basis preliminary analysis of ₹ 381.7 million is classified and disclosed as an exceptional item in the results for the quarter and nine months ended 31 December 2025. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate financial impact on the basis of such developments as needed.

b) The Company as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility. The said facility had been sold in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to ₹142.9 million had been classified and disclosed as an exceptional item in the results for the nine months ended 31 December 2025.

- 5 The Board of Directors at its meeting held on 13 February 2026 have declared an interim dividend of ₹ 43 (Rupees Forty Three only) per equity share (2150 % on the face value of ₹ 2 each) for the financial year ending 31 March 2026.
- 6 The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.

Place: Mumbai
Date: 13 February 2026

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Press Release

Alkem reports 11% revenue growth in Q3 FY26.

Mumbai, February 13, 2026: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the third quarter ended December 31, 2025. The Board of Directors took record of these results at its meeting held in Mumbai today.

Key Financial Metrics



Also, Alkem Laboratories announced the execution of a binding term sheet for acquiring a majority stake in Occlutech Holding AG (“Occlutech”), a global medical devices company, headquartered in Switzerland, specialising in minimally invasive cardiac implants, through its wholly-owned subsidiary Alkem MedTech Pvt Ltd (“Alkem MedTech”).

Commenting on this development, Sandeep Singh, Managing Director, Alkem Laboratories said, “This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment. With its significant presence in high-barrier markets, best-in-class R&D and manufacturing, and robust quality systems, Occlutech provides a strong lever for Alkem MedTech to expand into cardiovascular along with orthopaedics. Medtech is a natural extension for Alkem. In the company years, along with Enzene Biosciences, our Biotech arm, we expect Alkem MedTech to become meaningful growth pillar for the company.”

Commenting on the Q3 FY26 results, Dr. Vikas Gupta, CEO of Alkem, said, “In Q3, we delivered a stable performance in a dynamic operating environment, supported by strong fundamentals in our domestic business and consistent execution across our international businesses. We remain bullish on the growth opportunities in domestic as well as international business and are on track to deliver our full year guidance. Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets.”

Key highlights of Q3 FY26 financial performance

- Total Revenue from Operations was ₹37,368 million, with YoY growth of 10.7%.
 - India sales were ₹24,959 million, YoY growth of 5.5%.
 - International sales were ₹12,157 million, with YoY growth of 26.6%.
- Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were ₹8,280 million, resulting in an EBITDA margin of 22.2% vs. 22.5% in Q3 FY25. EBITDA grew by 9.0% YoY.
- R&D expenses for Q3 FY26 were ₹1,390 million, or 3.7% of total revenue from operations, vs. ₹1,312 million in Q3 FY25 at 3.9% of total revenue from operations.

- Profit before tax (after exceptional item) was ₹7,812 million, YoY growth of 6.9%.
- Net Profit (after Non-Controlling interest) was ₹6,360 million, YoY growth of 1.6%.
- Exceptional item for the quarter includes the impact of ₹ 528 million on a preliminary basis related to the notification by the Government of India regarding the four Labour Codes.
- According to IQVIA (SSA) data, for Q3 FY26:
 - The Company registered a growth of 9.8% YoY vs Indian Pharmaceutical Market (IPM), which grew by 10.9%.
 - Acute segment reported growth of 8.6% vs IPM which grew by 7.8%, 80 bps outperformance.
 - Chronic segment reported growth of 15.8% vs. IPM which grew by 15.6%, 18 bps outperformance.

Operational Highlights

Domestic Business – Q3 FY26 Key Highlights

- India sales were ₹24,959 million, YoY growth of 5.5%.
- The contribution of domestic sales to total sales in Q3 FY26 was 67.2% vs. 71.1% in Q3 FY25.
- As per IQVIA (SSA) data, during the quarter, we have outperformed IPM in six therapies: Anti-infectives grew by ~1.4X, VMN ~2.0X, Pain ~1.4X, Anti-Diabetic ~1.2X, Respiratory ~1.2X, and Derma ~1.8X.

International Business – Q3 FY26 Key Highlights

- International sales were ₹12,157 million, YoY growth of 26.6%.
- US sales were ₹7,533 million, YoY growth of 18.8%.
- US business sales contributed 20.3% to total sales in Q3 FY26.
- Non-US sales were ₹4,624 million, YoY growth of 41.6%.
- Non-US business sales contributed 12.5% to total sales in Q3 FY26.
- During Q3 FY26, for the US market, the Company filed 02 ANDA and received 07 ANDAs approvals.
- As of December 31, 2025, the Company had filed 188 ANDAs, 02 NDAs and 01 BLA with the USFDA. It has received approvals for 167 ANDAs (including 20 tentative approvals) and 02 NDAs.

Facility Regulatory Status

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Aug-19	EIR Received in Oct 2019
Taloja R&D (India)	Bioequivalence Centre	Apr-25	No observation
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Sep-25	No observation
Note: USFDA conducted a virtual inspection at our manufacturing facilities in Daman from October 5th to 7th, 2020.			

About Alkem: Alkem Laboratories Ltd. is the fifth-largest pharmaceutical company in the Indian market, with a legacy spanning over 50 years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 18 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring Healthier Lives” is at the core of the organization’s values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit www.alkemlabs.com and follow us on [LinkedIn](#), [Instagram](#), and [Facebook](#).

Contact

Investors:	Media:
Purvi Shah – Head of Investor Relations	Isha Trivedi
+91 84337 00890	+91 98925 90003
purvi.shah@alkem.com	alkemcorpcomm@alkem.com
+91-22-3982 9999 Ext: 9447	+91-22-3982 9999 Ext: 9672

Alkem Laboratories Ltd.

Q3 FY26 Results Presentation

13th February 2026



This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events, unless it is required by Law.

CONTENTS



Company's Financial Performance



Business Updates – Q3 FY26



Company overview and journey so far

Q3 FY26 Performance at Glance

Total Revenue from Operations

₹37,368 Mn

 **+10.7% YoY Growth**

EBITDA / Margin

₹8,280 Mn / 22.2%

 **+9.0% YoY Growth**

PAT¹ / Margin

₹6,360Mn / 17.0%

 **+1.6% YoY Growth**

Geographic-wise Break-Up

Domestic Business

₹24,959 Mn
+5.5% YoY Growth

International Business

₹12,157 Mn
+26.6% YoY Growth

Salient Numbers

₹55.9 Bn

Net Cash as of 31st Dec 2025

₹1,390 Mn

R&D spend for Q3 FY26

80 bps

Outperformance in the acute
segment vs. IPM

3.7%

R&D spend as % of sales during the
quarter

1. PAT: Profit after Non-Controlling Interest

Q3 FY26 – P&L Highlights

Particulars <i>(All figures in ₹ Mn)</i>	Q3FY26	Q3FY25	YoY growth	Q2FY26	QoQ growth	9MFY26	9MFY25	YoY growth
Revenue from Operations	37,368	33,743	10.7%	40,010	-6.6%	111,090	98,208	13.1%
Gross Profit	24,641	21,700	13.6%	26,000	-5.2%	72,641	63,358	14.7%
Gross Profit Margin	65.9%	64.3%		65.0%		65.4%	64.5%	
EBITDA	8,280	7,594	9.0%	9,208	-10.1%	24,878	21,209	17.3%
EBITDA Margin	22.2%	22.5%		23.0%		22.4%	21.6%	
PBT (before exceptional items)	8,340	7,311	14.1%	8,958	-6.9%	24,879	21,307	16.8%
Exceptional items¹	(528)	0		0		(399)	0	
PBT (after exceptional items)	7,812	7,311	6.9%	8,958	-12.8%	24,480	21,307	14.9%
PAT (after Non-Controlling interest)	6,360	6,258	1.6%	7,651	-16.9%	20,653	18,596	11.1%
PAT Margin	17.0%	18.5%		19.1%		18.6%	18.9%	
EPS (₹/share)	53.2	52.3	1.6%	64.0	-16.9%	172.8	155.5	11.1%

Notes: 1. Exceptional items for Q3 FY26 and 9M ended 31 Dec 2025 pertains to newly notified Labour Codes resulting in incremental impact; Exceptional items for 9M ended 31 Dec 2025, includes gain of ₹142.9 Mn from sale of the Indore facility.

CONTENTS



Company's Financial Performance




Business Updates – Q3 FY26



Company overview and journey so far

Domestic Business Performance

Q3 FY26 sales of ₹24,959 Mn (5.5% YoY growth)





- Domestic business¹ revenue grew by 5.5% YoY to ₹24,959 Mn from ₹23,649 Mn during the same period last year.
- Domestic revenue contributed 67.2% to total sales in Q3 FY26.
- According to IQVIA (SSA) data, for Q3 FY26:
 - The Company registered a growth of 9.8% YoY, vs. the Indian Pharmaceutical Market (IPM), which also grew by 10.9%.
 - We've grown faster than the market in six of IPM's key therapy areas.
 - We have outperformed in the acute segment by 80 bps, growing at 8.6% vs IPM growth of 7.8%.
 - We have marginally outperformed in chronic category, i.e. 18 bps registering a growth of 15.8% vs IPM growth of 15.6%.

1. Includes revenue from Adroit and Bombay Ortho businesses.

Q3 FY26 - outpacing the market growth in six of the key focus therapies

Alkem growth vs. IPM growth




Outperformance in 6 of the key IPM focus therapies

Therapy Class	Growth YoY %	Market share %	IPM Rank – Value
 Anti Infectives	2.8% 3.8%	13.5% ↑ +0.1%	1 ↔
 Gastro Intestinal	8.1% 7.4%	8.0% ↓ - 0.1%	3 ↔
 VMN	11.1% 21.8%	6.9% ↑ +0.6%	2 ↔
 Pain / Analgesics	8.0% 11.2%	5.5% ↑ +0.2%	3 ↔
 Anti Diabetic	14.8% ★ 17.2%	2.3% ↔	13 ↑ +2
 Neuro / CNS	11.8% 11.0%	2.4% ↔	8 ↔
 Respiratory	11.8% 14.4%	1.6% ↔	15 ↑ +1
 Derma	8.8% 15.9%	1.6% ↑ +0.1%	18 ↑ +1

15+ years of unmatched leadership in the Anti-Infectives therapy

Source: Market data as per IQVIA SSA Qtr. Dec'25; (1) GLP/GIP includes recent launches of molecules Semaglutide and Tirzepatide


Q3 FY26 US Business sales of ₹7,533 Mn (18.8% YoY growth)



- US business revenue grew by 18.8% YoY to ₹7,533 Mn from ₹6,340 Mn during the same period last year.
- The strong growth was mainly on account of continued growth traction in new launches and volume increase.
- US revenue contributed 20.3% to total sales in Q3 FY26.
- During the Q3 FY26, the Company filed 02 ANDA, received 07 ANDA's approval.

US Market Filing and approvals status


ANDA / BLA Filings



As of December 31, 2025, the Company has **filed 188 ANDAs, 2 NDAs and 1 BLA** and has **received 167 ANDAs approvals** (including 20 tentative approvals) **and 2 NDAs approvals**.

Non-US Business Performance

**Q3 FY26 sales of ₹4,624Mn
(41.6% YoY growth)**




- Non-US business revenue grew by 41.6% YoY to ₹4,624 Mn from ₹3,265 Mn during the same period last year.
- Non-US revenue contributed 12.5% to total sales in Q3 FY26.
- The Non-US business growth was driven by strong growth across all markets.

Facility Regulatory Status

Facility	Capability	Inspection Date	Regulatory Status
Baddi (India)	Formulations	Mar-24	EIR Received in June 2024
Daman (India)	Formulations	Aug-19	EIR Received in Oct 2019
Taloja R&D (India)	Bioequivalence Centre	Apr-25	No observation
Ankleshwar (India)	API	Apr-23	EIR Received in July 2023
Mandva (India)	API	Dec-23	EIR Received in Mar 2024
California (USA)	API	Sep-25	No observation

Note: USFDA conducted a virtual inspection at our manufacturing facilities in Daman from October 5th to 7th, 2020.

Shareholding Pattern as on Dec 31, 2025



■ Promoter & Promoter Group
 ■ Non-Institution
■ Institution

BSE Ticker	539523
NSE Symbol	ALKEM
Shares Outstanding (Mn)	120
MCap (Rs in Mn)*	658, 302
Free Float MCap (Rs in Mn)	309, 139
Industry	Pharmaceuticals

**Share Price - Rs 5, 507 from NSE as of 31st Dec 25.*

Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks

Non-Institution – Public, Other Bodies Corporates, Clearing Members, Non-Resident Indians, Hindu Undivided Family and Trusts

CONTENTS



Company's Financial Performance



Business Updates – Q3 FY26



Company overview and journey so far

Alkem Laboratories at Glance (FY25)



Market Leadership

#3

Rank in
Prescriptions¹

#5

Rank by value in
IPM²

Leading Player

In the Trade
Generics segment

Top 3

Player in 4 out of top
7 largest IPM's TAs²



Scale

₹1,29,645 Mn

Total Revenue³

70.2%


Domestic Revenue

18

Brand families worth
₹1000 Mn+²

12,500+

Field force⁴



Profitability

63.3%

Gross Profit
Margin

19.4%

EBITDA Margin

16.7%

PAT Margin

28.1%

ROCE (Pre-Tax)

1. Prescriptions data as per SMSRC MAT Mar'25; 2. Market data as per IQVIA SSA MAT Mar'25; 3. Including Other Operating Income; 4. Excluding Line Managers as of 31st March 2025

Strong momentum from our mega brands has been pivotal in building robust brand franchises and consistently scaling them over the years

#2 'PAN'

Biggest Brand family in the IPM

17 Brands

in the IPM Top 300 ranks

35 Brands

Among the Top 3 ranks in their CVM¹ (Brands > ₹250 Mn)

Building large brand families defines our identity...

Brand Families	MAT Mar'20	MAT Mar'25	CAGR (5 Yrs.)
> ₹10 Bn	0	1	16.1%
> ₹5 Bn	1	1	7.7%
> ₹1.5 Bn	6	11	10.4%
> ₹500 Mn	11	12	13.2%

Brand family > ₹5 Bn

PAN **CLAVAM**

Brand family > ₹1.5 Bn









TAXIM **SUMOL** **CHERi**

50+ years of Alkem journey – a snapshot



1973

Inception of Alkem Laboratories Limited

1978

Established the first plant at Taloja, Mumbai



2003

First R&D facility established at Taloja



2006

Taxim became India's first anti-infective drug to surpass annual sales figure of ₹ 1 billion in the domestic market



2007

Filed the first ANDA in the US for the drug Amlodipine

2015

Successfully completed Initial Public Offering (IPO)

2014

Clavam surpassed ₹ 2 billion domestic sales milestone



2012

Acquired an API manufacturing facility in the US



2011

Acquired Enzene Biosciences, a Company engaged in the development of biosimilars in India



2010

Acquired Ascend Laboratories, a pharmaceutical Company in the US



2009

Received the first ANDA approval in the US for the drug Amlodipine. Acquired Pharmacor Pty. Ltd., a generic pharmaceutical Company in Australia



2018

Revenue from the US market crossed US\$ 200 million in annual sales

2019

Crossed the revenue milestone of US\$ 1 billion

2020

Started a new biologic/ biosimilar manufacturing facility in Pune

TGx business delivered 10+ billion topline

2021

First product launched from Enzene Biosciences in India

Company forayed in the respiratory segment in India with the launch of Pulmocare division

2022

Awarded as "Pharma Company of the Year" in ET India Pharma World Awards 2023

PAN franchise crossed ₹ 10 billion sales milestone

Clavam crossed ₹ 6 billion sales milestone



2023

50 years of Alkem



2024 - 25

Inclusion in the MSCI India Index

Adroit acquisition

Entry into the Medtech segment via licensing agreement with Exactech and acquisition of Bombay Ortho

Alkem & key subsidiaries



THANK YOU

For any queries, contact:
Purvi Shah – Head of Investor Relations

Mobile: +91 84337 00890

E-mail: purvi.shah@alkem.com

Tel: +91 22 3982 9999 Ext: 9447

Stay updated on     

Disclaimer: This is a confidential email from Alkem Laboratories Limited. The contents of this email and any attachments are solely intended for the addressee(s) and in all likelihood contain information that is legally privileged. If you are not the intended recipient of this email, you are on notice of its status and we request you to kindly advise us by return email immediately. Please also simultaneously disregard the contents herein, delete this email from your computer and server and also destroy any physical copies, if created. You are hereby notified that any use, any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this e-mail, its contents or its attachment/s other than by its intended recipient/s is strictly prohibited and may be construed unlawful. Alkem Laboratories Limited does not accept any liability for the views expressed in this email or for the consequences of any viruses that may be transmitted with this email. The content of this email is subject to copyright and no part hereof may be reproduced, adapted or transmitted without the written consent of Alkem Laboratories Limited.